CNTA CENTESSA PHARMACEUTICALS PLC

Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference

Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference

BOSTON and LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that members of its management team will participate in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 8:00 a.m. ET.

A webcast of the fireside chat, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at .

About Centessa Pharmaceuticals 

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications. We operate with the conviction that each one of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit , which does not form part of this release.

Contact:

Kristen K. Sheppard, Esq.

SVP of Investor Relations



EN
02/02/2023

Underlying

CNTACENTESSA PHARMACEUTICALS PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CENTESSA PHARMACEUTICALS PLC

 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Reports Financial Results and Business Highli...

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected in all three indications this year with first-in-class potential in NT2 and IH ORX142 Phase 1 clinical trial for the treatment of select neurological and neurodegenerative disorders underway with d...

August 12, 2025 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Announces Clearance of Investigational New Dr...

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a Phase 1 clinical study of ORX142 in healthy volunteers. ORX142 is an investigational, novel, highly potent and selective OX2R agoni...

June 16, 2025 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferenc...

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2025 Global Healthcare Conference Date: June 4, 2025Fireside Chat: 11:40 AM ET Event: Goldman Sachs 46th Annual Global Healthcare ConferenceDate: June 10, 2025Fireside Chat: 9:20 AM ET Ac...

May 19, 2025 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Reports Financial Results and Business Highli...

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025 Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected across all three indications this year with first-in-class potential in NT2 and IHORX142 on track to initiate first-in-human studies for the treatment of neurological and neurodegenerative disorders w...

May 14, 2025 1 EN
 PRESS RELEASE
Free
CNTA CENTESSA PHARMA...

Centessa Pharmaceuticals Reports Business Highlights and Financial Res...

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024 Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) well underway and on track with data expected across all three indications in 2025 with first-in-class potential in NT2 and IHORX142 in IND-enabling studies for the treatment of neurological and neurodegenerative disorde...

March 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch